What Is Hematopoietic Growth Factor? Definition and What Research Reports
A hematopoietic growth factor is a secreted signalling protein — a cytokine — that regulates the survival, proliferation and maturation of blood-forming cells in bone marrow. The family includes named factors such as G-CSF, GM-CSF, erythropoietin and thrombopoietin. In peptide research the term appears in two ways: as the parent class for small peptide mimetics that bind the same receptors, and inside gene names. Published work has mapped G-CSF receptor distribution in human brain, examined regeneration after irradiation, and reviewed growth-factor support in oncology.
Definition
A hematopoietic growth factor is a secreted signalling protein — a cytokine — that binds a specific cell-surface receptor on blood-forming (hematopoietic) cells and regulates whether those cells survive, divide, or mature into a particular lineage. The word hematopoietic refers to the production of blood cells, and growth factor is the general term for a protein that carries an instruction between cells rather than acting as an enzyme or a structural component. The class is usually described as including granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), erythropoietin (EPO), thrombopoietin (TPO), stem cell factor (SCF) and several interleukins. These are glycoproteins — polypeptide chains with attached sugar groups — and they are considerably larger than the short synthetic peptides usually discussed under the heading of "research peptides."
This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about diagnosis, treatment, or a specific product.
What Class of Molecule Is It, and Where Does It Come From?
Hematopoietic growth factors are endogenous proteins, meaning the body produces them itself. Different members of the family originate in different tissues: bone marrow stromal cells, endothelial cells, macrophages and activated T lymphocytes are the sources usually named for the colony-stimulating factors and interleukins, while erythropoietin is associated chiefly with the kidney and thrombopoietin with the liver. Each factor acts through a matching receptor; receptor engagement triggers intracellular signalling cascades inside the responding cell.
Recombinant DNA technology allows several of these proteins to be manufactured outside the body, and recombinant versions of G-CSF, GM-CSF and erythropoietin exist as regulated pharmaceutical products in the United States and elsewhere. That regulatory status is a fact about the products, not a statement about any particular use; nothing on this page describes how any of them are administered.
Nomenclature at a glance
| Abbreviation | What the name refers to | Molecule type |
|---|---|---|
| G-CSF | Granulocyte colony-stimulating factor | Glycoprotein cytokine |
| GM-CSF | Granulocyte-macrophage colony-stimulating factor | Glycoprotein cytokine |
| EPO | Erythropoietin, named for the erythroid (red cell) lineage | Glycoprotein cytokine |
| TPO | Thrombopoietin, named for the platelet lineage | Glycoprotein cytokine |
| SCF | Stem cell factor | Glycoprotein cytokine |
The table lists naming conventions only. It is not a comparison of activity, potency or application.
How the Term Is Used in Peptide Research
The phrase turns up in peptide literature in two distinct ways, and confusing them is a common source of error.
- As the parent class for mimetics. Full-length hematopoietic growth factors are large glycoproteins, so a long-running research question has been whether much smaller molecules — including short peptides — can engage the same receptors. A 2001 conference review surveyed exactly this area under the title hematopoietic growth factor mimetics, and researchers used the term to describe compounds designed to reproduce receptor engagement without reproducing the full protein (PMID 11458500). This is the sense in which a reader browsing peptide literature is most likely to encounter the phrase.
- Inside gene and protein names. Some proteins carry "hematopoietic growth factor" in their formal name without being classical colony-stimulating factors. Hematopoietic growth factor inducible neurokinin-1, also known as Gpnmb or osteoactivin, is one example; a 2011 cross-species investigation reported that this protein functioned as a biomarker of progressive renal injury (PMID 21389974). The name reflects how the gene was originally identified, not the tissue where it matters most.
Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.
Try it freeWhat the Published Literature Reports
The verified papers below span haematology, oncology, neuroanatomy and nephrology, which gives a sense of how widely the term travels.
Regeneration after irradiation
A 2019 study in Stem Cell Reports examined CCR5 signalling and reported that it promoted murine and human hematopoietic regeneration following ionizing radiation (PMID 31155503). The work is relevant to the glossary entry because it illustrates that blood-forming recovery is governed by a broader signalling network than the classical growth-factor receptors alone; researchers in that study looked at a chemokine receptor rather than a colony-stimulating factor.
Distribution in human brain tissue
Hematopoietic growth factors are not confined to bone marrow. A 2014 paper in the Journal of Anatomy mapped the distribution of G-CSF and its receptor in the adult human brain with specific reference to Alzheimer's disease, and the study reported on where the factor and receptor were located in that tissue (PMID 24387791). Anatomical mapping of this kind describes presence and location; it is not a treatment finding.
Use of the term in clinical haematology and oncology
A 2011 report in Pediatric Hematology and Oncology described immunosuppressive therapy administered without hematopoietic growth factor exposure in children with acquired aplastic anemia (PMID 21707222). Separately, a 2013 article in Anti-Cancer Agents in Medicinal Chemistry addressed hematopoietic growth factor support in elderly patients treated with chemotherapy (PMID 24102275). Both titles show the phrase functioning as a standard clinical category — a shorthand for an entire supportive-care class — rather than as the name of a single molecule.
Adverse Events: What Studies Report
The verified sources indexed for this entry are definitional, anatomical, mechanistic or review-level, and none of them is a dedicated safety analysis, so no adverse-event rates, no doses and no durations are reproduced here. What can be said is narrower. The 2011 pediatric report was framed specifically around an immunosuppressive regimen delivered without hematopoietic growth factor exposure, which indicates that whether to include growth-factor support was treated as an open clinical question in that setting (PMID 21707222). The 2013 oncology review considered growth-factor support in an older population treated with chemotherapy, a group in which supportive-care decisions are routinely weighed separately from younger patients (PMID 24102275). Readers seeking a tolerability profile for any specific recombinant product would need the prescribing information and trial literature for that product, which is outside the scope of this glossary stub.
Tracking research? Log entries with dates, lots and notes — records, never plans.
Get the appLimits of the Term
- It is a class, not a compound. "Hematopoietic growth factor" names a family; statements about the family do not transfer to any individual member.
- It overlaps with "cytokine" and "colony-stimulating factor." Different papers draw the boundaries differently, and older literature is less consistent than recent work.
- A name containing the phrase is not proof of function. The Gpnmb/osteoactivin example shows that historical naming can point away from a protein's best-characterised role (PMID 21389974).
- Mimetic research is a separate literature. Findings about a full-length glycoprotein do not automatically describe a small-molecule or peptide mimetic of the same receptor, a distinction the 2001 review of hematopoietic growth factor mimetics was built around (PMID 11458500).
Related Terms
- Cytokine — the broader class of secreted signalling proteins that includes hematopoietic growth factors.
- Colony-stimulating factor — a subgroup named for colony formation in culture assays.
- Receptor agonist — any molecule that binds and activates a receptor, including mimetics of a larger native protein.
- Hematopoiesis — the process of blood cell formation that these factors regulate.
- Biomarker — a measurable indicator of a biological state, the role reported for Gpnmb in renal injury (PMID 21389974).
Want the full course? Every compound, evidence-graded and cited, inside PeptideU.
Start learning freeReferences
- CCR5 Signaling Promotes Murine and Human Hematopoietic Regeneration following Ionizing Radiation (Stem Cell Reports, 2019)
- Immunosuppressive therapy without hematopoietic growth factor exposure in pediatric acquired aplastic anemia (Pediatric Hematology and Oncology, 2011)
- Distribution of the hematopoietic growth factor G-CSF and its receptor in the adult human brain with specific reference to Alzheimer's disease (Journal of Anatomy, 2014)
- Hematopoietic growth factor mimetics (Annals of the New York Academy of Sciences, 2001)
- Hematopoietic growth factor inducible neurokinin-1 (Gpnmb/Osteoactivin) is a biomarker of progressive renal injury across species (Kidney International, 2011)
- Hematopoietic Growth Factor support in the Elderly treated with Chemotherapy (Anti-Cancer Agents in Medicinal Chemistry, 2013)
Frequently asked questions
Is a hematopoietic growth factor the same thing as a peptide?▾
Not in the usual sense. Hematopoietic growth factors are full-length glycoproteins — large, sugar-modified protein chains — while "research peptide" normally refers to much shorter sequences. The connection is that researchers have investigated smaller mimetics designed to engage the same receptors, an area surveyed in a 2001 review of hematopoietic growth factor mimetics (PMID 11458500).
Which molecules count as hematopoietic growth factors?▾
The class is usually described as including G-CSF, GM-CSF, erythropoietin, thrombopoietin, stem cell factor and several interleukins. Boundaries vary between papers, and the phrase is also used as a clinical category — for example, a 2013 review discussed hematopoietic growth factor support in elderly patients treated with chemotherapy without naming a single molecule (PMID 24102275).
Are these factors found outside bone marrow?▾
Published anatomy suggests yes. A 2014 study in the Journal of Anatomy mapped the distribution of G-CSF and its receptor in the adult human brain with specific reference to Alzheimer's disease, and the study reported where the factor and its receptor were located in that tissue (PMID 24387791). Mapping presence in tissue is descriptive and is not a treatment finding.
Why does a kidney biomarker have "hematopoietic growth factor" in its name?▾
Because protein names often reflect how a gene was first identified rather than where it matters most. Hematopoietic growth factor inducible neurokinin-1, also called Gpnmb or osteoactivin, was reported in a 2011 cross-species study to function as a biomarker of progressive renal injury (PMID 21389974). The name is historical, not a description of its primary role.
What does the literature say about blood-forming recovery after radiation?▾
A 2019 study in Stem Cell Reports examined CCR5 signalling and reported that it promoted murine and human hematopoietic regeneration following ionizing radiation (PMID 31155503). Researchers there studied a chemokine receptor rather than a classical colony-stimulating factor, which illustrates that recovery of blood cell production involves signalling beyond the named growth-factor receptors.
Do the cited papers describe doses or adverse events?▾
No. The verified sources for this entry are definitional, anatomical, mechanistic or review-level, so no doses, durations or adverse-event rates are reproduced here. One 2011 pediatric report was framed around immunosuppressive therapy given without hematopoietic growth factor exposure in acquired aplastic anemia, which indicates the question was treated as open in that setting (PMID 21707222).
Is "hematopoietic growth factor" a regulatory category?▾
It is primarily a biological and clinical class term. Separately, recombinant versions of several family members exist as regulated pharmaceutical products in various jurisdictions, which is a fact about those specific products rather than about the class. This page is educational only and is not medical advice; a licensed physician is the appropriate source for clinical questions.
Track it. Calculate it. Actually understand it.
References
This page summarises published research for education — it is not medical advice, and nothing here is a recommendation to use, purchase, or dose any substance. Study parameters described are what researchers reported, not instructions. Consult a qualified clinician before any health decision.